Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Disney

Johnson & Johnson

The Dow Jones Industrial Average has not exactly been keeping up with the other indices so far this year. That fact has left behind a number of undervalued Dow stocks for value investing.

The 3 Most Undervalued Dow Stocks to Buy Now: June 2023

Verizon

3M's dividend yield is up to 6%, following a 35% slump in its stock price. Walgreens' continued stock slide has driven its dividend yield up to 6.8%.

Hold Your Nose and Buy These High-Yield Dividend Stocks While They're Down

Walgreens stock trades for just 7x earnings guidance. Earnings are in decline, and the company's turnaround strategy appears to be little more than cost-cutting.

Walgreens Stock Might Be a Value Trap

Walgreens Boots Alliance, despite disappointing Q3 earnings and a significant cut in guidance, is an attractive investment for long-term, dividend-focused investors due to its high dividend yield and undervaluation. Walgreens' issues are temporary and not a threat to its financial viability due to the company's cost-cutting measures, stable operating expenses, recovering net income, and expanding margins. However, the potential risks include a possible recession, inflation, and healthcare-specific risks.

Walgreens Boots Alliance: A Buy For Yield Seekers After Q3 Earnings

While investors were already anticipating a miss and guidance revision for Walgreens Boots Alliance Inc (NASDAQ:WBA)'s third-quarter 2023, the results and revision came in even worse than expectations, UBS analysts wrote in a note to clients. The company blamed consumer and category conditions, lower COVID-19 contribution, and a more cautious macroeconomic view.

Walgreens guidance revision worse than expected, analysts write

DEERFIELD, Ill.--(BUSINESS WIRE)--Today, Walgreens announced its participation as the premier sponsor of Children with Diabetes (CWD), a nonprofit organization dedicated to providing education and support to families living with type 1 diabetes, at their upcoming Friends for Life (FFL) conference. Walgreens will serve as the exclusive pharmacy sponsor for the annual event, hosted July 4th – 9th in Orlando, Fla. FFL gathers dedicated experts, adults, children, and families with diabetes for a we.

Walgreens Deepens Commitment to Those Living with Diabetes at Children with Diabetes' Friends for Life Conference

With a Deutsche Bank downgrade, just two analysts have Outperform ratings or equivalents on Walgreens shares.

Will the Last Walgreens Stock Bull Please Turn Out the Lights

Automatic Data Processing

Albemarle

Cincinnati Financial

Clorox

Essex Property Trust

Hormel Foods

Medtronic

Realty Income Corp

Stanley Black & Decker

Sysco

Target

T. Rowe Price Group

V.F.

The ProShares S&P 500 Dividend Aristocrats ETF is recovering in June after a poor performance in May, with a 5.96% gain compared to a 5.90% loss in the previous month. Despite this, 31 dividend aristocrats are outperforming NOBL year-to-date through May. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After nearly 23 months, 2 of the 3 buy-and-hold portfolios continue to generate alpha over NOBL and all 3 are beating SPY.

My Best Dividend Aristocrats For July 2023

CVS Health

International Seaways

Lamb Weston Hlds

Quanta Services

Special situation stocks create event-driven opportunities for investors. Here are five that are worth a closer look.

5 Special Situation Stocks for Growth & Income

The story of the cautious consumer continues as Walgreens reflects on its latest quarterly earnings.   On Tuesday (June 27), after the company issued a warning that its profits are projected to fall below initial expectations, the stock of Walgreens Boots Alliance plummeted.

Walgreens Attributes Disappointing Results to Cautious Consumer Behavior

Frontier Communications Parent

GameStop

Procter & Gamble

Just as all cheap houses aren't a good buy, not all cheap stocks provide good value. Houses can have structural issues, such as a leaky roof or a broken HVAC system, or be in flood zones.

7 Value Stocks That Have Big Investors Running for the Exit

Walgreens Boots Alliance Inc (NASDAQ:WBA) will close 300 stores in the UK over the next year amid a shift to online shopping among the chemist's customers. Despite axing the number of its stores from 2,200 to 1,900, Boots will offer staff work at other locations rather than laying people off, according to reports.

Boots to close hundreds of stores amid online surge

Walgreens shares plummeted on Tuesday after the drugstore chain slashed its full-year earnings guidance, citing reduced consumer spending and slowing demand for COVID-19 products and services.

Walgreens Shares Plunge After Reducing Its Outlook as Spending Slows

Walgreens Boots Alliance, Inc. (NASDAQ:WBA ) Q3 2023 Earnings Conference Call June 27, 2023 8:30 AM ET Company Participants Tiffany Kanaga - Vice President, Global Investor Relations Roz Brewer - Chief Executive Officer James Kehoe - Chief Financial Officer John Driscoll - President of U.S. Healthcare Rick Gates - Senior Vice President and Chief Pharmacy Officer Conference Call Participants Lisa Gill - JP Morgan George Hill - Deutsche Bank Ann Hynes - Mizuho Securities Michael Cherny - Bank of America Merrill Lynch Lucas Romanski - TD Cowen A.J. Rice - Credit Suisse Elizabeth Anderson - Evercore ISI Eric Percher - Nephron Research Operator Good morning.

Walgreens Boots Alliance, Inc. (WBA) Q3 2023 Earnings Call Transcript

Walgreens Boots Alliance Inc. NASDAQ: WBA has trended lower since 2015 and could go lower. The Q3 results are mixed, but the guidance for Q4 and 2024 is weak.

How Low Can Walgreens Boots Alliance Go?

While Durable Goods Orders rose unexpectedly, Case-Shiller home prices fell for the second straight month, and Walgreens Boots Alliance missed on the bottom line.

Durables, Case-Shiller and Walgreens Mark a Busy Morning

Walgreens Boots' (WBA) U.S. Healthcare business expands, owing to key contract wins, continued partnership growth and a strong focus on execution.

Walgreens Boots' (WBA) Q3 Earnings Miss Estimates, Margins Down

Durable Orders Come in Much Higher Than Expected.

Durable Orders Come in Much Higher Than Expected

Walgreens Boots Alliance on Tuesday reported earnings that tumbled from the same time a year ago amid softening consumer spending and a pullback in demand for Covid vaccines.

Walgreens profit tumbles, slashes guidance amid significant drop in Covid vaccine demand

Walgreens slashed its annual earnings guidance as it continues to face waning demand for COVID vaccines and testing, which is cutting into its profits.

Walgreens slashes profit outlook as demand for COVID shots, tests wanes

Earnings per share declined 59% year over year. Revenue was up 8.6% over the third quarter of 2022.

Why Shares of Walgreens Are Dropping Tuesday

Walgreens Boots Alliance Inc (NASDAQ:WBA) shares tumbled almost 10% Tuesday morning after lagging consumer spending dragged the company's fiscal third-quarter earnings below expectations.  The retail pharmacy posted adjusted earnings of $1 per share, compared to expectations of $1.07 expected.

Walgreens stock sinks as middling consumer spending sours fiscal 3Q results

Walgreens Boots Alliance (NASDAQ: WBA ) stock is taking a beating on Tuesday after the company warned investors of lower earnings in its latest report. According to Walgreens Boots Alliance, several factors are weighing on its business for 2023.

Why Is Walgreens Boots Alliance (WBA) Stock Down 9% Today?

Walgreens Boots Alliance Inc (NASDAQ:WBA) reported fiscal third-quarter earnings that missed Wall Street's expectations, and lowered its full-year earnings guidance.

Blue-Chip Pharma Stock Hits 13-Year Low After Earnings

Shares of Walgreens Boots Alliance Inc. WBA, -10.37% tumbled 10.2% in morning trading Tuesday, enough to pace both the Dow Jones Industrial Average's DJIA, +0.28% and the S&P 500's SPX, +0.29% losers. The stock's selloff comes after the drugstore chain and health care services company's reported fiscal third-quarter profit that missed expectations and slashed its full-year outlook.

News for Walgreens Stock (WBA)